Updated Results of a Phase 2 Study of Biweekly Dose-Intense Paclitaxel Plus Gemcitabine (GEM/TAX) in Patients With Recurrent Locoregional or Metastatic Head-and-Neck Squamous Cell Carcinoma

Phase 2 ◽

Erratum: Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

Cancer ◽

10.1002/cncr.26531 ◽

2011 ◽

Vol 118 (9) ◽

pp. 2560-2560

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

Cancer ◽

10.1002/cncr.25769 ◽

2010 ◽

Vol 117 (10) ◽

pp. 2112-2119 ◽

Cited By ~ 66

Author(s):

Heather D. Brooks ◽

Bonnie S. Glisson ◽

B. Nebiyou Bekele ◽

Lawrence E. Ginsberg ◽

Adel El-Naggar ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study

Annals of Oncology ◽

10.1093/annonc/mdx374 ◽

2017 ◽

Vol 28 ◽

pp. v372 ◽

Cited By ~ 19

Author(s):

D. Zandberg ◽

A. Algazi ◽

A. Jimeno ◽

J.S. Good ◽

J. Fayette ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Preliminary Results ◽

A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.12.021 ◽

2018 ◽

Vol 100 (5) ◽

pp. 1307 ◽

Cited By ~ 5

Author(s):

L. Siu ◽

C. Even ◽

R. Mesía ◽

A. Daste ◽

J. Krauss ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study of “0-7-21” Hypofractionated Palliative Radiation Therapy for Advanced Head and Neck Squamous Cell Carcinoma

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2015.07.306 ◽

2015 ◽

Vol 93 (3) ◽

pp. S128

Author(s):

N.T.A. Nguyen ◽

L. Doerwald-Munoz ◽

J. Wright ◽

D.H. Kim ◽

S.M. Sagar ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Radiation Therapy ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Advanced Head ◽

Phase 2 ◽

Phase 2 Study ◽

Palliative Radiation Therapy

Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

Oral Oncology ◽

10.1016/j.oraloncology.2021.105192 ◽

2021 ◽

Vol 115 ◽

pp. 105192

Author(s):

Douglas R. Adkins ◽

Jin-Ching Lin ◽

Assuntina Sacco ◽

Jessica Ley ◽

Peter Oppelt ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Human Papillomavirus ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Randomized Phase 2

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(20)30327-2 ◽

2020 ◽

Vol 21 (9) ◽

pp. 1173-1187 ◽

Cited By ~ 6

Author(s):

Xu-Shan Sun ◽

Yungan Tao ◽

Christophe Le Tourneau ◽

Yoann Pointreau ◽

Christian Sire ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

High Risk ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

High Dose ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Abstract 5530: PD-L1 expression in patients screened for phase 2 head and neck squamous cell carcinoma clinical studies (HAWK and CONDOR)

10.1158/1538-7445.am2018-5530 ◽

2018 ◽

Cited By ~ 1

Author(s):

Sophie Wildsmith ◽

Marietta Scott ◽

Anita Midha ◽

Craig Barker ◽

Jessica Whiteley ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Clinical Studies ◽

Phase 2

An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps6102 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS6102-TPS6102 ◽

Cited By ~ 3

Author(s):

Bhumsuk Keam ◽

Makoto Tahara ◽

Jin-Ching Lin ◽

Assuntina Gesualda Sacco ◽

Bohuslav Melichar ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group ◽

Phase 2 Study ◽

International Multicenter

Faculty Opinions recommendation of Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738449325.793581438 ◽

2020 ◽

Author(s):

Sandra Nuyts ◽

Heleen Bollen

Keyword(s):

Squamous Cell Carcinoma ◽

High Risk ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

High Dose ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽